Company
Science
Medicines
- REVTORPYK®
- Patient Advocacy
Pipeline
Investors
Careers
- Our Culture
- Job Openings
Expanded Access Program

Press Releases

Investor Relations

Overview
Press Releases
Events & Presentations
Stock Information
- Stock Quote & Chart
- Historic Price Lookup
SEC Filings
Corporate Governance
Analyst Coverage
IR Resources

Year

November 9, 2026 Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

November 5, 2026 Celcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update

November 3, 2026 Celcuity To Participate in Upcoming Investor Conferences

October 29, 2026 Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call

October 24, 2026 Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

October 23, 2026 Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026

October 5, 2026 Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026

October 2, 2026 Celcuity Appoints David Gryska To Its Board Of Directors

September 30, 2026 Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States

September 1, 2026 Celcuity To Participate in Upcoming Investor Conferences